Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker RVMDW · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 6, 2026 | Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel… NCT07805954 · Pancreatic Cancer, Pancreatic Cancer Metastatic daraxonrasib, gemcitabine | RVMD Revolution Medicines, Inc. | Phase 3 | Recruiting | 400 | Mar 2029 | Registry ↗ |
| Nov 6, 2026 | Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice a… NCT07621718 · Pancreatic Cancer, Pancreatic Cancer Metastatic Zoldonrasib, Placebo | RVMD Revolution Medicines, Inc. | Phase 3 | Recruiting | 670 | Dec 30, 2028 | Registry ↗ |
| Nov 6, 2026 | Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) NCT06881784 · NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Can… daraxonrasib, docetaxel | RVMD Revolution Medicines, Inc. | Phase 3 | Recruiting | 590 | Dec 1, 2027 | Registry ↗ |
| Nov 4, 2026 | Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Li… NCT07777822 · NSCLC, Non-small Cell Lung Cancer zoldonrasib, Placebo | RVMD Revolution Medicines, Inc. | Phase 3 | Recruiting | 430 | Oct 2029 | Registry ↗ |
| Nov 4, 2026 | Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors NCT07397338 · Advanced Solid Tumors, Metastatic Solid Tumors Daraxonrasib, Elironrasib | RVMD Revolution Medicines, Inc. | Phase 1/2 | Recruiting | 370 | May 2029 | Registry ↗ |
| Oct 23, 2026 | Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) NCT07252232 · Pancreatic Cancer, PDAC daraxonrasib | RVMD Revolution Medicines, Inc. | Phase 3 | Recruiting | 500 | May 10, 2029 | Registry ↗ |
| Oct 19, 2026 | Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC NCT06162221 · Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated… RMC-6291, RMC-6236 | RVMD Revolution Medicines, Inc. | Phase 1/2 | Recruiting | 616 | Jun 2027 | Registry ↗ |
| Oct 2, 2026 | Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pa… NCT07491445 · Pancreatic Cancer, Pancreatic Cancer Metastatic daraxonrasib, gemcitabine | RVMD Revolution Medicines, Inc. | Phase 3 | Recruiting | 900 | Jun 2028 | Registry ↗ |
| Sep 22, 2026 | Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors NCT06445062 · Colorectal Cancer, CRC RMC-6236, mFOLFOX6 regimen | RVMD Revolution Medicines, Inc. | Phase 1/2 | Recruiting | 1,130 | Sep 30, 2028 | Registry ↗ |
| Sep 22, 2026 | Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With… NCT06128551 · Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer Elironrasib, Daraxonrasib | RVMD Revolution Medicines, Inc. | Phase 1/2 | Recruiting | 534 | Dec 2028 | Registry ↗ |
| Sep 17, 2026 | Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors NCT07349537 · Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) RMC-5127, daraxonrasib | RVMD Revolution Medicines, Inc. | Phase 1 | Recruiting | 574 | Apr 2028 | Registry ↗ |
| Sep 1, 2026 | Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Ade… NCT07573215 · PDAC, PDAC - Pancreatic Ductal Adenocarcinoma daraxonrasib | RVMD Revolution Medicines, Inc. | — | Approved for marketing | — | — | Registry ↗ |
| Jun 3, 2026 | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors NCT06040541 · Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) RMC-9805, RMC-6236 | RVMD Revolution Medicines, Inc. | Phase 1 | Recruiting | 604 | Dec 31, 2026 | Registry ↗ |
| Jun 2, 2026 | Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic… NCT06625320 · Pancreatic Cancer, PDAC RMC-6236, Gemcitabine | RVMD Revolution Medicines, Inc. | Phase 3 | Active, not recruiting | 500 | Jun 2026 | Registry ↗ |
| May 15, 2026 | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C… NCT05462717 · Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) RMC-6291 | RVMD Revolution Medicines, Inc. | Phase 1 | Active, not recruiting | 222 | Mar 31, 2027 | Registry ↗ |
| May 15, 2026 | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS NCT05379985 · Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) RMC-6236 | RVMD Revolution Medicines, Inc. | Phase 1/2 | Recruiting | 754 | May 31, 2027 | Registry ↗ |
| Jan 6, 2026 | Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure… NCT05054725 · Non-Small Cell Lung Cancer RMC-4630, Sotorasib | RVMD Revolution Medicines, Inc. | Phase 2 | Completed | 47 | Jul 3, 2024 | Registry ↗ |
| Apr 15, 2025 | Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors NCT04774952 · Solid Tumors RMC-5552 | RVMD Revolution Medicines, Inc. | Phase 1 | Completed | 58 | May 6, 2024 | Registry ↗ |
| Jun 26, 2023 | Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv… NCT03989115 · Solid Tumor RMC-4630, Cobimetinib | RVMD Revolution Medicines, Inc. | Phase 1/2 | Completed | 113 | Feb 8, 2022 | Registry ↗ |
| Sep 1, 2022 | Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors NCT03634982 · Solid Tumors RMC-4630 | RVMD Revolution Medicines, Inc. | Phase 1 | Unknown | 133 | Mar 31, 2023 | Registry ↗ |
20 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:20 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances